P
Peter C. Taylor
Researcher at University of Oxford
Publications - 397
Citations - 19020
Peter C. Taylor is an academic researcher from University of Oxford. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 63, co-authored 359 publications receiving 16347 citations. Previous affiliations of Peter C. Taylor include HealthPartners & University of Cambridge.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis
Ejaz Pathan,Sonya Abraham,Elizabeth Van Rossen,Robin Withrington,Andrew Keat,Peter Charles,E Paterson,Muslima Chowdhury,Catherine McClinton,Peter C. Taylor +9 more
TL;DR: Although a small pilot study, these results suggest that apremilast may be effective and well tolerated in AS and modulates biomarkers of bone biology and support further research of ap Remilast in axial inflammation.
Journal ArticleDOI
Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
Joel M. Kremer,Christopher T. Ritchlin,Alan M. Mendelsohn,Daniel Baker,L. Kim,Zhenhua Xu,J. Han,Peter C. Taylor +7 more
TL;DR: Inter intravenously administered golimumab plus MTX appears to have benefit in the longer-term reduction of RA signs/symptoms in MTX-resistant patients, with no unexpected safety concerns.
Journal ArticleDOI
VEGF and imaging of vessels in rheumatoid arthritis
TL;DR: These findings implicate vascular pannus in the erosive phase of disease and strongly suggest that proangiogenic molecules such as VEGF are targets for novel therapies in RA.
Journal ArticleDOI
Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients.
J. Bladon,Peter C. Taylor +1 more
TL;DR: It is demonstrated that ECP directly induces significant levels of apoptosis in lymphocytes of CTCL, GvHD and scleredema patients, and the apoptosis of these lymphocytes may contribute to the ECP effect.
Journal ArticleDOI
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.
Peter C. Taylor,Michael E. Weinblatt,Gerd R Burmester,Terence Rooney,Sarah Witt,C. Walls,Maher Issa,Claudia A. Salinas,Chadi Saifan,Xin Zhang,Anabela Cardoso,Miguel A. González-Gay,Tsutomu Takeuchi +12 more
TL;DR: To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately‐to‐severely active rheumatoid arthritis (RA).